KR20210073341A - Manufacturing method of herbal medicine mixed beverage with improved liver function and palatability and beverage produced by the same method - Google Patents
Manufacturing method of herbal medicine mixed beverage with improved liver function and palatability and beverage produced by the same method Download PDFInfo
- Publication number
- KR20210073341A KR20210073341A KR1020190164079A KR20190164079A KR20210073341A KR 20210073341 A KR20210073341 A KR 20210073341A KR 1020190164079 A KR1020190164079 A KR 1020190164079A KR 20190164079 A KR20190164079 A KR 20190164079A KR 20210073341 A KR20210073341 A KR 20210073341A
- Authority
- KR
- South Korea
- Prior art keywords
- beverage
- herbal medicine
- liver function
- jujube
- medicine mixed
- Prior art date
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000003908 liver function Effects 0.000 title claims abstract description 25
- 235000019629 palatability Nutrition 0.000 title claims abstract description 15
- 241000411851 herbal medicine Species 0.000 title claims description 65
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 52
- 230000000694 effects Effects 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 235000006533 astragalus Nutrition 0.000 claims abstract description 21
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 20
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 20
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 20
- 235000008397 ginger Nutrition 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 241001061264 Astragalus Species 0.000 claims abstract description 12
- 210000004233 talus Anatomy 0.000 claims abstract description 12
- 238000005406 washing Methods 0.000 claims abstract description 9
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 7
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 6
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 6
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 21
- 240000006891 Artemisia vulgaris Species 0.000 claims description 21
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 19
- 235000013976 turmeric Nutrition 0.000 claims description 19
- 210000001364 upper extremity Anatomy 0.000 claims description 19
- 240000002045 Guettarda speciosa Species 0.000 claims description 18
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 18
- 244000151018 Maranta arundinacea Species 0.000 claims description 14
- 235000010804 Maranta arundinacea Nutrition 0.000 claims description 14
- 235000012419 Thalia geniculata Nutrition 0.000 claims description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- 244000241838 Lycium barbarum Species 0.000 claims description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 12
- 238000003809 water extraction Methods 0.000 claims description 11
- 241000361919 Metaphire sieboldi Species 0.000 claims description 10
- 235000020733 paullinia cupana extract Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- 239000006049 herbal material Substances 0.000 claims description 3
- 235000019640 taste Nutrition 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 2
- 235000008434 ginseng Nutrition 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 72
- 239000008213 purified water Substances 0.000 abstract description 20
- 210000005228 liver tissue Anatomy 0.000 abstract description 16
- 210000002966 serum Anatomy 0.000 abstract description 14
- 150000002632 lipids Chemical class 0.000 abstract description 9
- 239000003673 groundwater Substances 0.000 abstract description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011575 calcium Substances 0.000 abstract description 4
- 229910052791 calcium Inorganic materials 0.000 abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 3
- 239000011707 mineral Substances 0.000 abstract description 3
- 235000008216 herbs Nutrition 0.000 abstract 2
- 239000008204 material by function Substances 0.000 abstract 2
- 240000001810 Angelica gigas Species 0.000 abstract 1
- 235000018865 Angelica gigas Nutrition 0.000 abstract 1
- 235000003106 Artemisia campestris Nutrition 0.000 abstract 1
- 241001249193 Artemisia campestris Species 0.000 abstract 1
- 241000533367 Cnidium officinale Species 0.000 abstract 1
- 206010013911 Dysgeusia Diseases 0.000 abstract 1
- 244000010000 Hovenia dulcis Species 0.000 abstract 1
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 241001619454 Wolfiporia Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 241000234314 Zingiber Species 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 241001247821 Ziziphus Species 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000010865 sewage Substances 0.000 description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 9
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 8
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 8
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 7
- 229960004245 silymarin Drugs 0.000 description 7
- 235000017700 silymarin Nutrition 0.000 description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 5
- 235000003097 Artemisia absinthium Nutrition 0.000 description 5
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 239000001138 artemisia absinthium Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 2
- 235000002657 Artemisia tridentata Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010089254 Cholesterol oxidase Proteins 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 241000383638 Allium nigrum Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000063156 Squatina squatina Species 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- VZWGHDYJGOMEKT-UHFFFAOYSA-J sodium pyrophosphate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O VZWGHDYJGOMEKT-UHFFFAOYSA-J 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료의 제조방법 및 이의 제조방법으로 제조된 음료에 관한 것이다. The present invention relates to a method for preparing a herbal medicine mixed beverage having improved liver function and improved palatability, and to a beverage prepared by the method.
간은 동물의 주요 기관중 하나로 해독작용, 단백질의 합성, 글리코겐과 같은 양분의 저장, 지방의 대사, 담즙과 요소의 생성 및 적혈구의 분해 등 여러 역할을 수행하며, 다양한 생화학적 작용을 조절하면서 평상시 건강의 유지를 위한 기본적인 조절기능을 가지고 있다.As one of the main organs of animals, the liver performs various roles such as detoxification, protein synthesis, storage of nutrients such as glycogen, metabolism of fat, production of bile and urea, and breakdown of red blood cells. It has basic control functions for maintaining health.
간은 우리 체내에서 독소로 인식될 수 있는 각종 약물이나 술, 기타 독성물질을 분해, 대사하여 배설될 수 있는 형태로 만들어 소변이나 담즙을 통해서 배출하는 작용을 한다. 간경변증 환자에서는 이러한 해독작용이 저하되어 약물, 술, 독성물질에 의한 위험성이 증가될 수 있으므로 유의하여야 한다. 그리고, 간은 중요한 면역기관이며 동시에 체내의 살균작용을 담당한다. 대장 점막을 통해서 혈액에 흡수되어 몸으로 들어간 균은 간을 거치면서 쿠퍼 세포라는 대식작용(균을 잡아먹는 기능)을 하는 세포에 의해 다 죽기 때문에 약 1% 미만의 세균만이 무사히 간을 통과해서 나갈 수 있다. 그러나 간경변증 환자에게서는 이 기능이 저하되어 각종 세균에 감염되기 쉬우며 대표적인 예가 여름철에 익히지 않은 어패류를 먹고 발생하는 비브리오 패혈증으로 특히 간경변증 환자에게서 집중적으로 발생한다.The liver decomposes, metabolizes and metabolizes various drugs, alcohol, and other toxic substances that can be recognized as toxins in our body and excretes them through urine or bile. In patients with liver cirrhosis, this detoxification effect is lowered, so the risk of drugs, alcohol, and toxic substances may increase. In addition, the liver is an important immune organ and at the same time is responsible for sterilizing the body. Bacteria that are absorbed into the blood through the large intestine mucosa and enter the body pass through the liver and die by the phagocytic cells called Kupffer cells, so only about 1% of the bacteria pass through the liver safely. can go out However, in patients with liver cirrhosis, this function is reduced and it is easy to be infected with various bacteria. A representative example is Vibrio sepsis caused by eating uncooked fish and shellfish in summer, which occurs intensively in patients with liver cirrhosis.
따라서 평소 간에 무리가 가지 않는 생활습관과 올바른 식생활, 적절한 운동을 통해 간을 보호하기 위한 노력이 필요하다. 하지만 현대인들은 바쁜 일상으로 인하여 이러한 건강관리를 위한 균형을 유지하는데 어려움을 겪고 있으므로 간의 건강 상태를 유지할 수 있도록 도움이 되는 식품을 섭취할 필요가 있다. Therefore, it is necessary to make an effort to protect the liver through a lifestyle that does not put strain on the liver, a correct diet, and appropriate exercise. However, modern people have difficulties in maintaining the balance for such health management due to their busy daily life, so it is necessary to consume foods that help maintain the health of the liver.
한편, 한국등록특허 제1930026호에 간기능 개선에 효능이 있는 흑마늘 음료의 제조방법이 개시되어 있고, 한국등록특허 제1817282호에 간기능 개선 및 항산화 활성이 증진된 새싹보리 혼합 음료의 제조방법이 개시되어 있지만, 본 발명의 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료의 제조방법 및 이의 제조방법으로 제조된 음료에 관해 개시된 바 없다. On the other hand, Korean Patent No. 1930026 discloses a method for producing a black garlic drink that is effective in improving liver function, and Korean Patent No. 1817282 discloses a method for preparing a mixed drink with improved liver function and antioxidant activity. Although disclosed, there is no disclosure with respect to a method for manufacturing a mixed beverage with herbal medicines having an effect on improving liver function and improving palatability of the present invention and a beverage prepared by the manufacturing method thereof.
본 발명은 상기와 같은 요구에 의해 도출된 것으로, 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 혼합한 다음 열수 추출하여 획득한 한약재 혼합 추출물의 제조방법을 제공하고, 상기 제조방법으로 제조된 한약재 혼합 추출물을 포함하는 음료가 간기능 개선에 효과적이며, 기호성이 향상되는 것을 확인함으로써, 본 발명을 완성하였다.The present invention has been derived from the above requirements, and herbal medicine mixture obtained by mixing turmeric, jujube, arrowroot, Sukjihwang, angelica, hwanggi, cheongung, gugija, dry ginger, upper extremity, bokryeong, wormwood and earth worm followed by hot water extraction. By providing a method for producing an extract, and confirming that a beverage containing a herbal medicine mixed extract prepared by the above method is effective in improving liver function and improving palatability, the present invention has been completed.
상기 과제를 해결하기 위하여, 본 발명은 In order to solve the above problems, the present invention
1) 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 세척한 후, 물과 상기 세척된 한약재를 혼합하는 단계; 및1) after washing turmeric, jujube, arrowroot, sukjihwang, angelica, hwanggi, cheongung, goji berry, dried ginger, upper extremity, bokryeong, injin mugwort and earth worm, mixing the washed herbal material with water; and
2) 상기 단계 1)의 한약재 혼합물을 열수 추출하는 단계;를 포함하는 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료의 제조방법을 제공한다.2) hot water extraction of the herbal medicine mixture of step 1) is effective in improving liver function, including; and provides a method for preparing a herbal medicine mixture beverage with improved palatability.
또한, 본 발명은 상기 제조방법으로 제조된 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료를 제공한다. In addition, the present invention is effective in improving liver function prepared by the above manufacturing method, and provides a herbal medicine mixed beverage with improved palatability.
본 발명은 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료의 제조방법 및 이의 제조방법으로 제조된 음료에 관한 것으로, 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 세척한 후, 상기 한약재를 혼합한 다음 열수 추출하여 한약재 혼합 추출물을 획득하는 단계;를 포함하여 제조된 한약재 혼합 음료는 알코올 처리에 의해 감소된 간 세포 재생율을 증진시키고, 동물 실험에서 알코올 섭취에 의해 증가된 혈중 알코올 함량 및 아세트알데히드의 함량을 감소시키고, 알코올 섭취에 의해 증가된 혈중 AST(aspartate transaminase) 및 ALT(alanine transaminase)의 활성을 감소시키며, 알코올 섭취에 의해 감소된 간 조직 내의 ADH(alcohol dehydrogenase) 및 ALDH(aldehyde dehydrogenase)의 활성을 증가시키며, 알코올 섭취에 의해 증가된 혈청 및 간 조직의 지질을 감소시키는 것을 확인하였다. 또한, 상기 간기능 개선 효과를 확인한 본 발명의 음료는 이취 및 이미가 나지 않고 소비자들의 기호에 부합한다는 이점이 있다. The present invention relates to a method for manufacturing a herbal medicine blend beverage having improved liver function and improved palatability and a beverage prepared by the method, and relates to turmeric, jujube, arrowroot, Sukjihwang, Angelica, Hwanggi, cheongung, gugija, and dry ginger. After washing the upper extremities, bokryeong, wormwood, and earth worm, the herbal medicines are mixed and then hot water extraction to obtain a herbal medicine mixture extract; herbal medicine mixture beverages prepared including alcohol treatment promotes reduced liver cell regeneration rate In animal experiments, it reduces the blood alcohol content and acetaldehyde content increased by alcohol ingestion, and reduces the activity of aspartate transaminase (AST) and alanine transaminase (ALT) in the blood increased by alcohol intake. It was confirmed that increased the activity of ADH (alcohol dehydrogenase) and ALDH (aldehyde dehydrogenase) in liver tissue decreased by alcohol intake, and decreased serum and liver tissue lipids increased by alcohol intake. In addition, the beverage of the present invention, which has confirmed the liver function improvement effect, has the advantage that it does not have off-flavors and images, and conforms to the preferences of consumers.
더욱이 혼합물 추출시, 일반 정제수를 사용하는 것 이외에 염지하수를 추가로 혼합함으로써 고농축 천연 용존 미네랄 및 수용성 칼슘을 음료에 포함할 수 있고, 염지하수의 기능성 물질을 음료에 포함함으로써 손쉽게 섭취할 수 있다는 장점이 있다. Moreover, when extracting the mixture, in addition to using general purified water, highly concentrated natural dissolved minerals and water-soluble calcium can be included in the beverage by additionally mixing salted groundwater, and the functional substance of salted sewage can be easily consumed by including the functional material in the beverage. There is this.
도 1은 본 발명의 한약재 혼합 음료의 알코올 손상에 대한 세포 재생능을 확인한 결과이다. CON은 음성대조군이고, 실리마린은 양성대조군이다. 실험예 1은 일반 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이고, 실험예 2는 염지하수가 포함된 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이다.
도 2는 알코올을 섭취한 동물모델에서 본 발명의 한약재 혼합 음료에 의한 혈중 알코올 농도 변화(A) 및 아세트알데히드 농도 변화(B)를 확인한 결과이다. NC는 음성대조군이고, EtOH CON은 알코올만 섭취한 대조군이며, 실리마린은 양성대조군이다. 실험예 1은 일반 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이고, 실험예 2는 염지하수가 포함된 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이다.
도 3은 알코올을 섭취한 동물모델에서 본 발명의 한약재 혼합 음료에 의한 혈중 AST 활성 변화(A) 및 ALT 활성 변화(B)를 측정한 결과이다. NC는 음성대조군이고, EtOH CON은 알코올만 섭취한 대조군이며, 실리마린은 양성대조군이다. 실험예 1은 일반 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이고, 실험예 2는 염지하수가 포함된 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이다.
도 4는 알코올을 섭취한 동물모델에서 본 발명의 한약재 혼합 음료에 의한 혈중 ADH 활성 변화(A) 및 ALDH 활성 변화(B)를 측정한 결과이다. NC는 음성대조군이고, EtOH CON은 알코올만 섭취한 대조군이며, 실리마린은 양성대조군이다. 실험예 1은 일반 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이고, 실험예 2는 염지하수가 포함된 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료 섭취군이다. 1 is a result of confirming the cell regeneration ability for alcohol damage of the herbal medicine mixed beverage of the present invention. CON is a negative control and silymarin is a positive control. Experimental Example 1 is a beverage intake group containing a herbal medicine mixed extract extracted using general purified water, and Experimental Example 2 is a beverage intake group containing a herbal medicine mixture extract extracted using purified water containing saline sewage.
Figure 2 is the result of confirming the change in blood alcohol concentration (A) and acetaldehyde concentration change (B) by the herbal medicine mixed drink of the present invention in an animal model ingesting alcohol. NC is a negative control, EtOH CON is an alcohol-only control, and silymarin is a positive control. Experimental Example 1 is a beverage intake group containing a herbal medicine mixed extract extracted using general purified water, and Experimental Example 2 is a beverage intake group containing a herbal medicine mixture extract extracted using purified water containing saline sewage.
3 is a result of measuring changes in blood AST activity (A) and ALT activity change (B) by the herbal medicine mixed drink of the present invention in an animal model ingesting alcohol. NC is a negative control, EtOH CON is an alcohol-only control, and silymarin is a positive control. Experimental Example 1 is a beverage intake group containing a herbal medicine mixed extract extracted using general purified water, and Experimental Example 2 is a beverage intake group containing a herbal medicine mixture extract extracted using purified water containing saline sewage.
4 is a result of measuring the change in blood ADH activity (A) and ALDH activity change (B) by the herbal medicine mixed drink of the present invention in an animal model ingesting alcohol. NC is a negative control, EtOH CON is an alcohol-only control, and silymarin is a positive control. Experimental Example 1 is a beverage intake group including a herbal medicine mixture extract extracted using normal purified water, and Experimental Example 2 is a beverage intake group containing a herbal medicine mixture extract extracted using purified water containing saline sewage.
본 발명은 the present invention
1) 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 세척한 후, 물과 상기 세척된 한약재를 혼합하는 단계; 및1) after washing turmeric, jujube, arrowroot, sukjihwang, angelica, hwanggi, cheongung, goji berry, dried ginger, upper extremity, bokryeong, injin mugwort and earth worm, mixing the washed herbal material with water; and
2) 상기 단계 1)의 한약재 혼합물을 열수 추출하는 단계;를 포함하는 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료의 제조방법에 관한 것이다. 2) hot water extraction of the herbal medicine mixture of step 1) is effective in improving liver function, including; and relates to a method for producing a herbal medicine mixture beverage with improved palatability.
상기 단계 1)의 혼합은 물 100L에 대하여 울금 0.5~1.5kg, 대추 0.25~0.75kg, 칡 0.25~0.75kg, 숙지황 0.05~0.15kg, 당귀 0.05~0.15kg, 황기 0.05~0.15kg, 천궁 0.05~0.15kg, 구기자 0.1~0.2kg, 건생강 0.1~0.3kg, 상지 0.5~1.5kg, 복령 0.05~0.15kg, 인진쑥 0.02~0.07kg 및 지구자 0.25~0.75kg을 혼합하는 것이고, 바람직하게는 물 100L에 대하여 울금 0.8~1.2kg, 대추 0.4~0.6kg, 칡 0.4~0.6kg, 숙지황 0.08~0.12kg, 당귀 0.08~0.12kg, 황기 0.08~0.12kg, 천궁 0.08~0.12kg, 구기자 0.13~0.17kg, 건생강 0.15~0.25kg, 상지 0.8~1.2kg, 복령 0.08~0.12kg, 인진쑥 0.04~0.06kg 및 지구자 0.4~0.6kg을 혼합하는 것이며, 더 바람직하게는 물 100L에 대하여 울금 1kg, 대추 0.5kg, 칡 0.5kg, 숙지황 0.1kg, 당귀 0.1kg, 황기 0.1kg, 천궁 0.1kg, 구기자 0.15kg, 건생강 0.2kg, 상지 1kg, 복령 0.1kg, 인진쑥 0.05kg 및 지구자 0.5kg을 혼합하는 것이지만, 이에 한정하는 것은 아니다. The mixing of step 1) is 0.5~1.5kg of turmeric, 0.25~0.75kg of jujube, 0.25~0.75kg of arrowroot, 0.05~0.15kg of shuangihuang, 0.05~0.15kg of angelica, 0.05~0.15kg of Astragalus, 0.05~0.15kg of cheongung per 100L of water. 0.15kg, 0.1~0.2kg Goji berry, 0.1~0.3kg dry ginger, 0.5~1.5kg upper extremity, 0.05~0.15kg bokryeong, 0.02~0.07kg Injin mugwort, and 0.25~0.75kg of earth berry, preferably 100L of water About turmeric 0.8~1.2kg, jujube 0.4~0.6kg, arrowroot 0.4~0.6kg, sukhumang 0.08~0.12kg, angelica 0.08~0.12kg, astragalus 0.08~0.12kg, cheongung 0.08~0.12kg, wolfberry 0.13~0.17kg, 0.15 to 0.25 kg of dried ginger, 0.8 to 1.2 kg of upper limb, 0.08 to 0.12 kg of bokryeong, 0.04 to 0.06 kg of wormwood, and 0.4 to 0.6 kg of earthworm, more preferably 1 kg of turmeric, 0.5 kg of jujube per 100 L of water , arrowroot 0.5kg, Sukhumi Hwang 0.1kg, Angelica 0.1kg, Astragalus 0.1kg, Chunkyung 0.1kg, Goji berry 0.15kg, dry ginger 0.2kg, upper extremity 1kg, Bokryeong 0.1kg, Injin mugwort 0.05kg, and Earth berry 0.5kg. The present invention is not limited thereto.
상기 단계 2)의 열수 추출은 80~120℃에서 3~5시간 동안 추출하는 것일 수 있고, 바람직하게는 90~110℃에서 3~5시간 동안 추출하는 것이며, 더 바람직하게는 100℃에서 4시간 동안 추출하는 것이지만, 이에 한정하는 것은 아니다. The hot water extraction in step 2) may be extraction at 80-120° C. for 3-5 hours, preferably at 90-110° C. for 3-5 hours, and more preferably at 100° C. for 4 hours. During extraction, but is not limited thereto.
본 발명의 일 구현 예에서 상기 단계 1)의 물은 순수한 물 또는 염지하수가 혼합된 물을 사용할 수 있고, 바람직하게는 정제수 또는 5~15%(v/v)의 염지하수가 포함된 정제수를 사용할 수 있으며, 더 바람직하게는 10%(v/v)의 염지하수가 포함된 정제수를 사용하는 것이지만, 이에 제한되는 것은 아니다. In one embodiment of the present invention, the water in step 1) may be pure water or water mixed with saltwater, preferably purified water or purified water containing 5-15% (v/v) saltwater. It can be used, and more preferably, purified water containing 10% (v/v) salted sewage is used, but is not limited thereto.
본 발명의 용어 '염지하수'는 육지에서 스며든 담수와 바다에서 흘러든 해수가 합쳐져 생성된 것으로, 물속에 녹아있는 염분(鹽分) 등 총 용존 고형물(總溶存固形物)의 함량이 2,000㎎/L 이상인 암반대수층 안의 지하수이다. The term 'saltwater' as used in the present invention is produced by combining fresh water permeated from the land and seawater flowing from the sea, and has a total dissolved solids content such as salt dissolved in the water of 2,000 mg/ It is groundwater in rock aquifers above L.
염지하수는 높은 미네랄 함량을 보이며, 수온은 16~18℃, pH는 7.3~7.5로 저온 안정성과 계절변동 및 특성변화가 적은 물리적 장점이 있으며, 외부환경에 노출되지 않아 일반세균, 중금속 등 유해성분이 없는 청정한 수자원이다. Saltwater has a high mineral content, and the water temperature is 16~18℃ and the pH is 7.3~7.5, so it has low-temperature stability and physical advantages with little seasonal variation and characteristic change. It is not exposed to the external environment, so it is free from harmful components such as general bacteria and heavy metals. There is no clean water resource.
본 발명의 염지하수는 염지하수를 획득할 수 있는 곳이라면 어느 곳이라도 상관 없으나, 바람직하게는 경상북도 울진군에서 획득한 염지하수를 사용하였다. The salt sewage of the present invention may be anywhere as long as it can be obtained. Preferably, salt sewage obtained from Uljin-gun, Gyeongsangbuk-do was used.
상기 한약재 혼합 음료는 상기 단계 2) 이후에, 한약재 혼합 열수 추출물 100 중량부에 대하여 타우린 0.1~0.5 중량부, 과라나 추출물 분말 0.05~0.15 중량부 및 사양벌꿀 1.5~2.5 중량부를 추가로 더 혼합할 수 있고, 바람직하게는 한약재 혼합 열수 추출물 100 중량부에 대하여 타우린 0.2~0.4 중량부, 과라나 추출물 분말 0.08~0.12 중량부 및 사양벌꿀 1.9~2.3 중량부를 추가로 더 혼합하는 것이며, 더 바람직하게는 한약재 혼합 열수 추출물 100 중량부에 대하여 타우린 0.33 중량부, 과라나 추출물 분말 0.11 중량부 및 사양벌꿀 2.18 중량부를 추가로 더 혼합하는 것이지만, 이에 제한되는 것은 아니다. The herbal medicine mixed drink is after step 2), 0.1 to 0.5 parts by weight of taurine, 0.05 to 0.15 parts by weight of guarana extract powder, and 1.5 to 2.5 parts by weight of specification honey based on 100 parts by weight of the herbal medicine mixed hot water extract. Preferably, 0.2 to 0.4 parts by weight of taurine, 0.08 to 0.12 parts by weight of guarana extract powder, and 1.9 to 2.3 parts by weight of specification honey are further mixed with respect to 100 parts by weight of herbal medicine mixed hot water extract, more preferably herbal medicine mixture With respect to 100 parts by weight of the hot water extract, 0.33 parts by weight of taurine, 0.11 parts by weight of guarana extract powder, and 2.18 parts by weight of specification honey are further mixed, but is not limited thereto.
본 발명의 일 구현 예에서, 상기 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료는 바람직하게는In one embodiment of the present invention, the herbal medicine mixed beverage having an effect on improving liver function and improving palatability is preferably
1) 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 세척한 후, 물 100L에 대하여 상기 세척된 울금 0.5~1.5kg, 대추 0.25~0.75kg, 칡 0.25~0.75kg, 숙지황 0.05~0.15kg, 당귀 0.05~0.15kg, 황기 0.05~0.15kg, 천궁 0.05~0.15kg, 구기자 0.1~0.2kg, 건생강 0.1~0.3kg, 상지 0.5~1.5kg, 복령 0.05~0.15kg, 인진쑥 0.02~0.07kg 및 지구자 0.25~0.75kg을 혼합하는 단계; 및1) After washing turmeric, jujube, arrowroot, Sukjihwang, angelica, hwanggi, cheongung, gugija, dried ginger, upper extremity, bokryeong, injin mugwort and earth worm, 0.5~1.5kg of washed turmeric, 0.25~0.75 jujube per 100L of water kg, arrowroot 0.25~0.75kg, red sagebrush 0.05~0.15kg, angelfish 0.05~0.15kg, astragalus 0.05~0.15kg, cheongung 0.05~0.15kg, wolfberry 0.1~0.2kg, dry ginger 0.1~0.3kg, upper extremity 0.5~1.5kg , mixing bokryeong 0.05-0.15kg, injin mugwort 0.02-0.07kg and gujaja 0.25-0.75kg; and
2) 상기 단계 1)의 한약재 혼합물을 80~120℃에서 3~5시간 동안 열수 추출하는 단계;를 포함하여 제조될 수 있고, 2) extracting the herbal medicine mixture of step 1) with hot water at 80 to 120° C. for 3 to 5 hours; can be prepared including,
더 바람직하게는 more preferably
1) 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 세척한 후, 물 100L에 대하여 상기 세척된 울금 0.8~1.2kg, 대추 0.4~0.6kg, 칡 0.4~0.6kg, 숙지황 0.08~0.12kg, 당귀 0.08~0.12kg, 황기 0.08~0.12kg, 천궁 0.08~0.12kg, 구기자 0.13~0.17kg, 건생강 0.15~0.25kg, 상지 0.8~1.2kg, 복령 0.08~0.12kg, 인진쑥 0.04~0.06kg 및 지구자 0.4~0.6kg을 혼합하는 단계; 및1) After washing turmeric, jujube, arrowroot, sukjihwang, angelica, hwanggi, cheongung, gugija, dried ginger, upper extremity, bokryeong, injin mugwort and earth worm, 0.8~1.2kg of washed turmeric, 0.4~0.6 of jujube per 100L of water kg, kudzu 0.4~0.6kg, red sagebrush 0.08~0.12kg, angelica 0.08~0.12kg, astragalus 0.08~0.12kg, cheongung 0.08~0.12kg, wolfberry 0.13~0.17kg, dry ginger 0.15~0.25kg, upper extremity 0.8~1.2kg , mixing bokryeong 0.08-0.12kg, injin mugwort 0.04~0.06kg and guinea pig 0.4-0.6kg; and
2) 상기 단계 1)의 한약재 혼합물을 90~110℃에서 3~5시간 동안 열수 추출하는 단계;를 포함하여 제조될 수 있으며, 2) extracting the herbal medicine mixture of step 1) with hot water at 90 to 110° C. for 3 to 5 hours; can be prepared including,
더욱더 바람직하게는even more preferably
1) 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 세척한 후, 물 100L에 대하여 상기 세척된 울금 1kg, 대추 0.5kg, 칡 0.5kg, 숙지황 0.1kg, 당귀 0.1kg, 황기 0.1kg, 천궁 0.1kg, 구기자 0.15kg, 건생강 0.2kg, 상지 1kg, 복령 0.1kg, 인진쑥 0.05kg 및 지구자 0.5kg을 혼합하는 단계; 및1) After washing turmeric, jujube, kudzu, sukjihwang, angelica, hwanggi, cheongung, goji berry, dried ginger, upper extremity, bokryeong, injin mugwort and earth worm, 1 kg of washed turmeric, 0.5 kg of jujube, 0.5 kg of arrowroot per 100L of water , Sukjihwang 0.1kg, Angelica 0.1kg, Astragalus 0.1kg, Chrysanthemum 0.1kg, Goji berry 0.15kg, dry ginger 0.2kg, upper extremity 1kg, Bokryeong 0.1kg, Injin mugwort 0.05kg, and Astragalus 0.5kg; and
2) 상기 단계 1)의 한약재 혼합물을 100℃에서 4시간 동안 열수 추출하는 단계;를 포함하여 제조되는 것이지만, 이에 한정하는 것은 아니다. 2) hot water extraction of the herbal medicine mixture of step 1) at 100° C. for 4 hours; but is not limited thereto.
또한, 본 발명은 상기 제조방법으로 제조된 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료에 관한 것이다.In addition, the present invention relates to a herbal medicine mixed beverage having an effect on improving liver function and having improved palatability prepared by the above manufacturing method.
상기 음료는 간기능 개선 효과가 있고, 이취 및 이미가 나지 않아 소비자 기호도가 향상되는 효과가 있다. The beverage has an effect of improving liver function, and there is no off-flavor and no image, so that consumer preference is improved.
이하, 제조예 및 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 제조예 및 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail using Preparation Examples and Examples. These preparations and examples are only for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited thereto.
제조예 1. 배합 재료에 따른 한약재 혼합 추출물의 제조Preparation Example 1. Preparation of herbal medicine mixture extract according to compounding materials
한약재 혼합 음료의 제조를 위해, 하기 표 1에 개시된 바와 같이 한약재를 혼합한 후, 100℃에서 4시간 동안 열수 추출하였다.For the preparation of herbal medicine mixed drinks, herbal medicines were mixed as shown in Table 1 below, followed by hot water extraction at 100° C. for 4 hours.
제조예 2. 배합비에 따른 한약재 추출물의 제조Preparation Example 2. Preparation of herbal medicine extract according to the mixing ratio
배합비에 따른 한약재 혼합 음료를 제조를 위해, 하기 표 2에 개시된 바와 같이 배합비에 따라 한약재를 혼합한 후, 100℃에서 4시간 동안 열수 추출하였다.To prepare a herbal medicine mixed beverage according to the mixing ratio, herbal medicines were mixed according to the mixing ratio as shown in Table 2 below, followed by hot water extraction at 100° C. for 4 hours.
제조예 3. 염지하수를 첨가한 정제수를 이용한 한약재 추출물의 제조Preparation Example 3. Preparation of herbal medicine extract using purified water to which salted groundwater was added
상기 실험예 1과 동일한 배합으로 한약재 추출물을 제조하되, 염지하수가 10%(v/v) 포함된 정제수를 사용하여 열수 추출하였다(실험예 2).An herbal medicine extract was prepared in the same formulation as in Experimental Example 1, but hot water extraction was performed using purified water containing 10% (v/v) salted groundwater (Experimental Example 2).
본 발명에 사용된 염지하수는 염지하수 1L 당 칼슘이온 1168.7mg, 마그네슘이온 1001mg, 칼륨이온 103.4mg, 나트륨이온 8757.7mg을 포함하고 있다. The salted sewage used in the present invention contains 1168.7 mg of calcium ions, 1001 mg of magnesium ions, 103.4 mg of potassium ions, and 8757.7 mg of sodium ions per 1 L of salted sewage.
염지하수를 첨가한 정제수를 이용하여 한약재 추출물을 제조한 후, 성분 분석을 의뢰한 결과, 첨가하지 않은 나트륨 및 칼슘이 각각 56.4mg/100ml, 19.6mg/100ml 측정되었으며, 이는 수용성 나트륨과 칼슘은 해양암반수에서 기인된 것으로 추정된다. After preparing an herbal medicine extract using purified water with added saltwater, as a result of requesting component analysis, sodium and calcium without addition were measured at 56.4mg/100ml and 19.6mg/100ml, respectively, which means that water-soluble sodium and calcium are It is presumed to originate from the bedrock water.
제조예 4. 타우린, 과라나 추출물 분말 및 사양벌꿀이 혼합된 한약재 혼합 음료의 제조Preparation Example 4. Preparation of herbal medicine mixed beverage in which taurine, guarana extract powder and specification honey are mixed
상기 실험예 1과 동일한 배합으로 제조된 한약재 혼합 열수 추출물 100 중량부에 대하여 타우린 0.33 중량부, 과라나 추출물 분말 0.11 중량부 및 사양벌꿀 2.18 중량부를 추가로 더 혼합하여 한약재 혼합 음료를 제조하였다(실험예 3). 0.33 parts by weight of taurine, 0.11 parts by weight of guarana extract powder, and 2.18 parts by weight of specification honey were further mixed with respect to 100 parts by weight of herbal medicine mixed hot water extract prepared in the same formulation as in Experimental Example 1 to prepare a herbal medicine mixed drink (Experimental Example 3).
과라나 추출물의 분말은 과라나 열수 추출물을 분말화한 후, 덱스트린과 혼합한 것이다. The powder of the guarana extract is obtained by pulverizing the guarana hot water extract and mixing it with dextrin.
실시예 1. 한약재 혼합 음료의 간기능 개선 효과Example 1. Liver function improvement effect of herbal medicine mixed beverage
상기 실험예 1 및 실험예 2의 한약재 혼합 추출물의 간기능 개선 효과를 확인하였다. The liver function improvement effect of the herbal medicine mixture extract of Experimental Example 1 and Experimental Example 2 was confirmed.
1) 알코올에 의해 손상된 간 세포의 재생활성 측정1) Measurement of regenerative activity of liver cells damaged by alcohol
실험에 사용된 일반 간 세포(Chang cell)는 한국 세포주 은행(KCLB)으로부터 분양받아 사용하였으며, 10%(v/v) FBS를 첨가한 DMEM 배지를 사용하여 37℃, 5% CO2 배양기에서 배양하였다. The normal liver cells (Chang cells) used in the experiment were purchased from the Korea Cell Line Bank (KCLB) and cultured in a DMEM medium supplemented with 10% (v/v) FBS at 37° C., 5% CO 2 incubator. did.
세포 재생활성은 세포 생존율을 측정하여 확인하였으며, 세포 생존율은 MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 분석 방법을 이용하였다. Cell regeneration activity was confirmed by measuring the cell viability, and the cell viability was measured using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) analysis method.
구체적으로, 96 웰 플레이트에 1×105cells/well로 세포를 동일하게 분주하고, 24시간 동안 배양한 후, 각 시료를 100㎍/mL의 농도가 되도록 배지에 첨가한 다음 37℃, 5% CO2 배양기에서 24시간 동안 재배양하였다. 음성대조군(CON)을 제외한 모든 군에 5%(v/v) 에탄올을 처리하고, 24시간 후 상층액을 제거한 뒤 MTT 용액을 첨가하고 3시간 동안 추가 배양하였다. 그 후, 상층액을 제거하고 200㎕의 DMSO(dimethyl sulfoxide)를 첨가한 다음 불용성의 포즈마잔 크리스탈(formazan crystal)을 용해한 후, 상기 용해액을 570nm에서 흡광도를 측정하여 세포 생존율을 계산하였다. 측정 결과는 음성대조군에 대한 상대적 세포 생육도(relative cell viability)로 표기하였다. Specifically, the cells were equally distributed at 1×10 5 cells/well in a 96-well plate, and after culturing for 24 hours, each sample was added to the medium to a concentration of 100 μg/mL, and then at 37° C., 5% CO 2 Cultivation was carried out in an incubator for 24 hours. All groups except for the negative control group (CON) were treated with 5% (v/v) ethanol, and after 24 hours, the supernatant was removed, MTT solution was added, and further incubated for 3 hours. Thereafter, the supernatant was removed, 200 μl of dimethyl sulfoxide (DMSO) was added, and then insoluble formazan crystal was dissolved, and the absorbance of the lysate was measured at 570 nm to calculate cell viability. Measurement results were expressed as relative cell viability with respect to the negative control group.
그 결과, 도 1에 개시된 바와 같이 본 발명의 실험예 1 및 실험예 2는 에탄올 첨가에 의해 감소된 세포 생존율을 증가시키므로, 간 세포 재생활성이 있다는 것을 확인하였다.As a result, as shown in Figure 1, Experimental Example 1 and Experimental Example 2 of the present invention increase the cell viability decreased by the addition of ethanol, and thus it was confirmed that there is a liver cell regeneration activity.
2) 알코올을 섭취한 동물모델에서 간기능 개선 효과 확인2) Confirmation of liver function improvement effect in animal model consuming alcohol
- 실험동물 및 분류- Experimental animals and classification
생후 5주령(130~150g)된 SD(Sprague-Dawley)계 수컷 흰쥐를 오리엔트바이오(Gyeonggi-do, Korea)로부터 분양 받아, 1주일 동안 순화시켰다. 그 후, 6주령이 되었을 때 난괴법(randomized block design)으로 그룹을 분리하였다. Five-week-old (130-150 g) SD (Sprague-Dawley) male rats were distributed from Orient Bio (Gyeonggi-do, Korea) and acclimatized for one week. Then, at the age of 6 weeks, the groups were separated by a randomized block design.
사육실의 온도는 22℃, 습도는 55%를 유지하였으며, 6시부터 18시까지 일광조절을 유지하는 환경에서 사육하였다. 적응기간 동안 동물들의 특이사항을 관찰하여 기록하였으며, 식이와 물은 자유로이 섭취할 수 있도록 하였다. The temperature of the breeding room was 22℃ and the humidity was 55%, and the breeding was carried out in an environment that maintains daylight control from 6:00 to 18:00. During the adaptation period, the animal's peculiarities were observed and recorded, and food and water were freely ingested.
- 실험군 처치방법- How to treat the experimental group
실험 그룹은 음성대조군(NC), 알코올 투여군(EtOH CON), 양성대조군으로 에탄올 및 실리마린 2.5 또는 5mg/kg BW 투여군, 본 발명의 실험예 1(일반 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료) 및 실험예 2(염지하수가 포함된 정제수를 이용하여 추출한 한약재 혼합 추출물을 포함하는 음료)를 250 또는 500mg/kg BW 투여한 군으로 분류하였다. The experimental group was a negative control group (NC), an alcohol administration group (EtOH CON), a positive control group administered with ethanol and silymarin 2.5 or 5 mg/kg BW, Experimental Example 1 of the present invention (a beverage containing a herbal medicine mixed extract extracted using general purified water) ) and Experimental Example 2 (a beverage containing a herbal medicine mixed extract extracted using purified water containing salted groundwater) was classified into a group administered with 250 or 500 mg/kg BW.
알코올과 시험물질은 흰 쥐의 kg 단위 체중 당 2mL 용량으로 경구 투여하였다. 또한, 사료 섭취로 인해 나타날 수 있는 위장관을 통한 알코올의 흡수 방해 현상을 배재하기 위해 알코올을 경구 투여하기 전 18시간 동안 절식시킨 후, 1주 동안은 20%(v/v) EtOH을 처리한 후 30분 후 시험 물질을 급여하였으며, 2주째는 40%(v/v) EtOH을 처리한 후 30분 후 시험 물질을 급여하였다. Alcohol and test substance were orally administered at a dose of 2 mL per kg body weight of white rats. In addition, in order to exclude a phenomenon that interferes with the absorption of alcohol through the gastrointestinal tract, which may occur due to feed intake, after fasting for 18 hours before oral administration of alcohol, after treatment with 20% (v/v) EtOH for 1 week After 30 minutes, the test substance was fed, and on the second week after 40% (v/v) EtOH was treated, the test substance was fed 30 minutes later.
혈중 에탄올 농도, 아세트알데히드 농도 및 효소 활성을 측정하기 위해 14일 째 투여 후 18시간 동안 절식 시킨 뒤 15일 째 알코올과 각각의 시료를 경구 투여 하였으며, 알코올 투여 3시간 후 마취시켜 복부 하대정맥에서 혈액을 채취하였다. 채취한 혈액은 4℃, 3,000rpm에서, 15분간 원심 분리하여 혈청을 분리하였으며, 분리된 혈청으로부터 알코올 및 아세트알데히드 농도, AST, AST, ADH 및 ALDH 효소 활성을 측정하였고, 지질함량을 분석하였다. To measure blood ethanol concentration, acetaldehyde concentration and enzyme activity, after administration on the 14th day, fasting for 18 hours, alcohol and each sample were orally administered on the 15th day. was collected. The collected blood was centrifuged at 4° C., 3,000 rpm for 15 minutes to separate serum, alcohol and acetaldehyde concentrations, AST, AST, ADH and ALDH enzyme activities were measured from the separated serum, and lipid content was analyzed.
적출한 실험동물의 간 조직은 PBS(phosphate buffered saline) 용액에 여러 번 세척하여 표면의 이물질을 제거한 후 칭량하였고, 액체 질소에 급냉시킨 후 시료 분석 시까지 -70℃에서 보관 후 간 조직의 지질 함량 분석에 사용하였다. The liver tissue of the extracted experimental animal was washed several times in PBS (phosphate buffered saline) solution to remove foreign substances on the surface, then weighed, quenched in liquid nitrogen and stored at -70°C until sample analysis. Lipid content of liver tissue used for analysis.
- 결과- result
① 혈중 알코올 및 아세트알데히드 측정① Measurement of blood alcohol and acetaldehyde
혈중 알코올 농도는 Bucher(1951)의 방법을 이용하여 제조한 에탄올 측정용 kit(R-Biopharm, Germany)로 분석하였다. 이인산 칼륨 완충액(Potassium diphosphate buffer, pH 9.0) 3ml에 NAD 1 타블렛(0.8mg)을 녹인 후, 0.1mL의 혈청을 첨가한 다음 3분 동안 반응시켰다. 그 후 340nm에서 흡광도 측정한 값을 A1이라 하고, 다시 0.05mL의 ADH를 가하여 5분 동안 반응시킨 후 340nm에서 흡광도 측정한 값을 A2라 하였으며, 알코올 농도는 하기 식 1과 같이 계산하였다.Blood alcohol concentration was analyzed using a kit for ethanol measurement (R-Biopharm, Germany) prepared using the method of Bucher (1951). After dissolving 1 tablet of NAD (0.8 mg) in 3 ml of potassium diphosphate buffer (pH 9.0), 0.1 mL of serum was added and reacted for 3 minutes. After that, the absorbance value measured at 340 nm was referred to as A1, and 0.05 mL of ADH was added and reacted for 5 minutes. Then, the absorbance value measured at 340 nm was referred to as A2, and the alcohol concentration was calculated as in Equation 1 below.
[식 1][Equation 1]
알코올(mmol/L)=[(V×MW)/(ε×d×v×2×1000)]×ΔAAlcohol (mmol/L)=[(V×MW)/(ε×d×v×2×1000)]×ΔA
V: 최종 부피V: final volume
v: 샘플 부피v: sample volume
MW: 분석에 사용된 기질의 분자량MW: molecular weight of the substrate used in the analysis
d: 빛 통로(light path)d: light path
ε: 340nm에서 NADH의 소화 계수(extinction coefficient)=6.3ε: Extinction coefficient of NADH at 340 nm = 6.3
ΔA: (A2-A1)샘플-(A2-A1)공백(blank)ΔA: (A2-A1) sample-(A2-A1) blank
혈청 아세트알데히드 농도는 Lundquist(1974)의 방법을 이용하여 제조한 아세트알데히드 측정용 kit(R-Biopharm, Germany)로 분석하였다. 이인산 칼륨 완충액(Potassium diphosphate buffer, pH 9.0) 3ml에 NAD 1 타블렛(0.8mg)을 녹인 후, 0.2mL의 혈청을 첨가한 다음 3분 동안 반응시켰다. 그 후 340nm에서 흡광도 측정한 값을 A1이라 하고, 다시 0.05mL의 ALDH를 가하여 5분 동안 반응시킨 후 340nm에서 흡광도 측정한 값을 A2라 하였으며, 아세트알데히드 농도는 알코올 농도 계산식과 동일하게 계산하였다.Serum acetaldehyde concentration was analyzed using the acetaldehyde measurement kit (R-Biopharm, Germany) prepared using the method of Lundquist (1974). After dissolving 1 tablet of NAD (0.8 mg) in 3 ml of potassium diphosphate buffer (pH 9.0), 0.2 mL of serum was added and reacted for 3 minutes. After that, the absorbance value measured at 340 nm was called A1, and 0.05 mL of ALDH was added and reacted for 5 minutes. The absorbance value measured at 340 nm was called A2, and the acetaldehyde concentration was calculated in the same manner as in the alcohol concentration calculation formula.
그 결과, 도 2에 개시된 바와 같이 알코올 투여에 의해 증가된 알코올 농도 및 아세트알데히드 농도가 본 발명의 실험예 1 및 실험예 2 처리에 의해 감소하는 것을 확인하였다. As a result, as shown in FIG. 2 , it was confirmed that the alcohol concentration and acetaldehyde concentration increased by the alcohol administration were decreased by the treatment of Experimental Examples 1 and 2 of the present invention.
② 혈중 AST 및 ALT 효소 활성 측정② Measurement of AST and ALT enzyme activity in blood
혈중 AST 측정은 Reitman-Frankel(1957)의 방법을 이용하여 제조한 AST-ALT 측정용 kit(AM 101, Asan, Korea)를 사용하여 측정하였다. 기질액(α-케토글루탐산, L-아스파르트산) 1mL을 37℃에서 5분 동안 전 반응 시키고 혈청 0.2mL을 첨가하여 37℃에서 1시간 동안 반응한 다음 정색시약(2,4-dinitro phenylhydrazine) 1mL을 첨가하여 실온에서 20분간 방치한 후 0.4N NaOH 10mL을 첨가하여 반응을 중지한 다음 505nm에서 증류수를 대조로 흡광도를 측정하였다. AST 활성치는 표준용액의 검량선에 기준하여 산출하였다. Blood AST was measured using the AST-ALT measurement kit (AM 101, Asan, Korea) prepared using the method of Reitman-Frankel (1957). 1 mL of substrate solution (α-ketoglutamic acid, L-aspartic acid) was pre-reacted at 37°C for 5 minutes, 0.2 mL of serum was added, and reacted at 37°C for 1 hour, followed by 1 mL of coloring reagent (2,4-dinitro phenylhydrazine) was added and left at room temperature for 20 minutes, the reaction was stopped by adding 10 mL of 0.4N NaOH, and then the absorbance was measured at 505 nm with distilled water as a control. The AST activity value was calculated based on the calibration curve of the standard solution.
혈중 ALT 측정은 Reitman-Frankel(1957)의 방법을 이용하여 제조한 AST-ALT 측정용 kit(AM 101, Asan, Korea)를 사용하여 측정하였다. 기질액(α-케토글루탐산, L-아스파르트산) 1mL을 37℃에서 5분 동안 전 반응 시키고 혈청 0.2mL을 첨가하여 37℃에서 1시간 동안 반응한 다음 정색시약(2,4-dinitro phenylhydrazine) 1mL을 첨가하여 실온에서 20분간 방치한 후 0.4N NaOH 10mL을 첨가하여 반응을 중지한 다음 505nm에서 증류수를 대조로 흡광도를 측정하였다. ALT 활성치는 표준용액의 검량선에 기준하여 산출하였다. Blood ALT was measured using the AST-ALT measurement kit (AM 101, Asan, Korea) prepared using the method of Reitman-Frankel (1957). 1 mL of substrate solution (α-ketoglutamic acid, L-aspartic acid) was pre-reacted at 37°C for 5 minutes, 0.2 mL of serum was added, and reacted at 37°C for 1 hour, followed by 1 mL of coloring reagent (2,4-dinitro phenylhydrazine) was added and left at room temperature for 20 minutes, the reaction was stopped by adding 10 mL of 0.4N NaOH, and then the absorbance was measured at 505 nm with distilled water as a control. ALT activity was calculated based on the calibration curve of the standard solution.
그 결과, 도 3에 개시된 바와 같이 알코올 투여에 의해 증가된 AST 및 ALT 활성이 본 발명의 실험예 1 및 실험예 2 처리에 의해 감소하는 것을 확인하였다. As a result, as shown in FIG. 3 , it was confirmed that the AST and ALT activities increased by alcohol administration were decreased by the treatment of Experimental Examples 1 and 2 of the present invention.
③ 혈중 ADH 및 ALDH 효소 활성 측정③ Measurement of ADH and ALDH enzyme activity in blood
간 조직 내 ADH 활성도는 Bergmeyer의 방법(1974)에 의하여 측정하였다. 0.2M NaOH/글리신 버퍼(pH 9.6)에 0.67mM NAD 용액과 효소액 0.05mL를 첨가하여 37℃에서 5분간 전 반응시켰다. 그 후, 100mM 에탄올을 첨가하여 혼합한 다음 즉시 340nm에서 흡광도를 측정하였다. 상기 용액을 다시 37℃에서 5분간 반응시킨 후, 340nm에서의 흡광도로 NADH의 생성량을 측정하고 표준 검량선을 이용하여 활성도를 산출하였다. 효소의 활성도는 1분간 1mg의 단백질이 생성한 NADH의 양을 nmol로 표기하였다.ADH activity in liver tissue was measured by Bergmeyer's method (1974). To 0.2M NaOH/glycine buffer (pH 9.6), 0.67mM NAD solution and 0.05mL of an enzyme solution were added, followed by pre-reaction at 37°C for 5 minutes. Thereafter, 100 mM ethanol was added and mixed, and the absorbance was immediately measured at 340 nm. After reacting the solution at 37° C. for 5 minutes, the amount of NADH production was measured by absorbance at 340 nm, and the activity was calculated using a standard calibration curve. The enzyme activity was expressed in nmol as the amount of NADH produced by 1 mg of protein per minute.
ALDH 활성도는 Koivula와 Koivusalo 방법(1975)을 이용하여 측정하였다. 0.1M 피로인산사나트륨 버퍼(tetrasodium pyrophosphate decahydrate buffer)에 13.3mM NAD 용액, 16.7mM 피라졸 용액 그리고 효소액 0.05mL를 첨가하여 37℃에서 5분간 전 반응시켰다. 여기에 60mM 프로피온알데히드(propionaldehyde) 용액을 첨가한 후 즉시 340nm에서 흡광도를 측정하였다. 그 후 상기 용액을 다시 37℃에서 5분간 반응시켜 반응종료 후 340nm에서의 흡광도로 NADH의 생성량을 측정하였고 표준 검량선을 이용하여 그 활성도를 산출하였다. 효소의 활성도는 1분간 1mg의 단백질이 생성한 NADH의 양을 nmol로 표기하였다.ALDH activity was measured using the Koivula and Koivusalo method (1975). 13.3mM NAD solution, 16.7mM pyrazole solution and 0.05mL of enzyme solution were added to 0.1M tetrasodium pyrophosphate decahydrate buffer, and the reaction was carried out at 37°C for 5 minutes. Absorbance was measured at 340 nm immediately after addition of 60 mM propionaldehyde solution. Then, the solution was reacted again at 37° C. for 5 minutes to measure the amount of NADH produced by absorbance at 340 nm after completion of the reaction, and the activity was calculated using a standard calibration curve. The enzyme activity was expressed in nmol as the amount of NADH produced by 1 mg of protein per minute.
그 결과, 도 4에 개시된 바와 같이 알코올 투여에 의해 감소되었던 ADH 및 ALDH 활성이 본 발명의 실험예 1 및 실험예 2 처리에 의해 증가하는 것을 확인하였다. As a result, as shown in FIG. 4 , it was confirmed that the ADH and ALDH activities, which were decreased by alcohol administration, were increased by the treatment of Experimental Examples 1 and 2 of the present invention.
④ 혈중 및 간 조직의 지질 함량 측정④ Measurement of lipid content in blood and liver tissue
혈중 및 간 조직의 총 콜레스테롤은 Allain 등(1974)의 효소법을 응용한 측정용 시약(AM 202-K, 아산제약)을 사용하여 측정하였다. 혈청 콜레스테롤은 CE(cholesterol ester) 및 유리 콜레스테롤 두 형태로 존재하므로, 이들 모두를 정량하기 위하여 혈청 중 에스테르형의 콜레스테롤을 콜레스테롤에스테라제(cholesterol esterase)에 의해, 지방산과 유리형 콜레스테롤을 콜레스테롤산화효소(cholesterol oxidase)에 의해 Δ4-콜레스텐온(cholestenon)으로 바꾸어 과산화효소와 기질인 H2O2, 페놀, 4-아미노-안티피린을 혼합하여 적색으로 발색시키고 500nm에서 흡광도를 측정한 후 콜레스테롤 표준곡선과 비교하여 정량하였다. Total cholesterol in blood and liver tissue was measured using a reagent (AM 202-K, Asan Pharmaceutical) that applied the enzyme method of Allain et al. (1974). Since serum cholesterol exists in two forms, CE (cholesterol ester) and free cholesterol, in order to quantify both, ester-type cholesterol in serum is converted to cholesterol esterase, and fatty acid and free cholesterol are converted to cholesterol oxidase. (cholesterol oxidase) to Δ4-cholestenon, a mixture of peroxidase and substrate H 2 O 2 , phenol, and 4-amino-antipyrine to develop a red color. After measuring the absorbance at 500 nm, the standard curve for cholesterol was compared with .
간 조직 콜레스테롤은 Folch 등(Folch et al., 1957)의 방법을 수정하여 사용하였다. 간 조직 1g을 취한 후 6mL 클로로포름:메탄올(2:1, v/v) 용액과 2mL 증류수로 균질화하고, 상기 균질액을 4℃, 1,000rpm에서, 10분간 원심분리하여 하층액(클로로포름 층)을 획득한 후 분석에 이용하였다. 하층액 500㎕를 취한 후 24시간 동안 자연건조시키고, 50㎕ 트립톤X100:클로로포름(1:1, v/v) 용액을 첨가한 후 섞어주었다. 그 후 450㎕ 클로로포름으로 희석한 뒤 총량이 500㎕가 되도록 하고 이 용액 10㎕를 취한 후 12시간 동안 건조시켜 측정에 사용하였다.Liver tissue cholesterol was used by modifying the method of Folch et al. (Folch et al., 1957). After taking 1 g of liver tissue, it was homogenized with a 6 mL chloroform: methanol (2:1, v/v) solution and 2 mL distilled water, and the homogenate was centrifuged at 4 ° C, 1,000 rpm for 10 minutes to obtain a lower layer (chloroform layer). After acquisition, it was used for analysis. After taking 500 μl of the lower layer, it was dried naturally for 24 hours, and 50 μl tryptone X100: chloroform (1:1, v/v) solution was added and mixed. Then, after dilution with 450 μl chloroform, the total amount was 500 μl, and 10 μl of this solution was dried for 12 hours and used for measurement.
혈청 및 간 조직 지질추출물 중 중성지질 정량은 효소법에 의한 정량용 kit 시약(AM 157S-K, 아산제약)으로 측정하였다. 간 조직 지질추출물은 총 콜레스테롤 정량과 동일하게 하층액을 사용하였으며, 하층액 10㎕를 취하여 12시간 동안 자연건조 시킨 후 50㎕ 메탄올로 용해시켜 kit로 정량하였다. Quantification of neutral lipids in serum and liver tissue lipid extracts was measured with kit reagent (AM 157S-K, Asan Pharmaceutical) for quantification by enzymatic method. The liver tissue lipid extract was used in the same manner as the total cholesterol quantification, and 10 µl of the lower supernatant was dried naturally for 12 hours and then dissolved in 50 µl methanol and quantified with a kit.
혈청 및 간 조직의 HDL-C(High density lipoprotein cholesterol)의 정량은 효소법에 의한 정량용 kit 시약(AM 203, 아산제약)으로 측정하였다. 간 조직 지질추출물은 총 콜레스테롤 정량과 동일한 방법으로 추출하여 측정에 사용하고, 콜레스테롤 표준액과 비교하여 정량하였다. Quantification of HDL-C (High density lipoprotein cholesterol) in serum and liver tissue was measured with a kit reagent (AM 203, Asan Pharmaceutical) for quantification by enzymatic method. The liver tissue lipid extract was extracted and used in the same method as the quantification of total cholesterol, and was quantified by comparison with a standard cholesterol solution.
혈청 및 간 조직의 LDL-C(Low density lipoprotein cholesterol)의 정량은 중성지질 함량이 400mg/dL 이상일 때 Friedewald 공식에 의해 계산되므로, 하기 식 2에 의해 계산하였다. Quantification of LDL-C (Low Density Lipoprotein Cholesterol) in serum and liver tissue is calculated by the Friedewald formula when the triglyceride content is 400 mg/dL or more, so it was calculated by
[식 2][Equation 2]
LDL-C=TC-[HDL-C+(TG/5)LDL-C=TC-[HDL-C+(TG/5)
동맥경화지수(Athrogenic index, AI)는 하기 식 3에 의해 계산하였다. Arteriosclerosis index (Athrogenic index, AI) was calculated by Equation 3 below.
[식 3][Equation 3]
AI=[(TC-HDL-C)]/HDL-CAI=[(TC-HDL-C)]/HDL-C
그 결과, 하기 표 3에 개시된 바와 같이 알코올 투여에 의해 증가되었던 혈중 TG, TC, LDL-C 및 동맥경화지수가 본 발명의 실험예 1 및 실험예 2 처리에 의해 감소하였고, 알코올 투여에 의해 감소하였던 HDL-C는 본 발명의 실험예 1 및 실험예 2 처리에 의해 증가하는 것을 확인하였다. As a result, as shown in Table 3 below, blood TG, TC, LDL-C and arteriosclerosis index, which were increased by alcohol administration, were decreased by the treatment of Experimental Examples 1 and 2 of the present invention, and decreased by alcohol administration It was confirmed that the HDL-C was increased by the treatment of Experimental Example 1 and Experimental Example 2 of the present invention.
또한, 하기 표 4에 개시된 바와 같이 알코올 투여에 의해 증가되었던 간 조직의 TG 및 TC가 본 발명의 실험예 1 및 실험예 2 처리에 의해 감소하였다. In addition, as shown in Table 4 below, TG and TC of liver tissue, which were increased by alcohol administration, were decreased by the treatment of Experimental Examples 1 and 2 of the present invention.
(mg/dL)TG
(mg/dL)
(mg/dL)TC
(mg/dL)
(mg/dL)HDL-C
(mg/dL)
(mg/dL)LDL-C
(mg/dL)
(Silymarin)positive control
(Silymarin)
(mg/g)TG
(mg/g)
(mg/g)TC
(mg/g)
(Silymarin)positive control
(Silymarin)
실시예 2. 한약재 혼합 음료의 관능검사Example 2. Sensory test of herbal medicine mixed beverage
본 발명의 한약재 혼합 음료의 관능검사는 30~50대 여성 15명 및 남성 15명 총 30명을 대상으로 실시하였다. 맛, 향, 색감, 종합적 기호도에 대한 관능검사는 9점 척도법을 사용하여 진행하였으며, 점수가 높을수록 긍정적 평가를 의미한다.The sensory test of the herbal medicine mixed beverage of the present invention was conducted on a total of 30 subjects in their 30s and 50s, 15 females and 15 males. The sensory test for taste, aroma, color, and overall preference was conducted using a 9-point scale method, and a higher score means a more positive evaluation.
1) 배합 재료에 따른 한약재 혼합 추출물이 포함된 음료1) Beverage containing herbal medicine mixed extracts according to the ingredients
배합 재료에 따른 한약재 혼합 추출물이 포함된 음료의 관능검사 결과, 색감의 차이는 실험예 1, 비교예 1 및 비교예 2에서 거의 없었으나, 실험예 1은 쓴맛이 중화되고, 한약재 특유의 향이 감소하여 비교예 1 및 비교예 2에 비해 쉽게 섭취할 수 있었고, 종합 기호도가 가장 현저하였다. As a result of the sensory test of the beverage containing the herbal medicine mixed extract according to the compounding material, there was almost no difference in color in Experimental Example 1, Comparative Example 1, and Comparative Example 2, but in Experimental Example 1, the bitter taste was neutralized and the characteristic flavor of the herbal medicine was reduced. Therefore, compared to Comparative Examples 1 and 2, it could be easily ingested, and the overall preference was the most remarkable.
2) 배합비 재료에 따른 한약재 혼합 추출물2) Herbal medicine mixed extract according to the ingredients
배합비에 따른 한약재 혼합 추출물이 포함된 음료의 관능검사 결과, 색감의 차이는 실험예 1, 비교예 3 및 비교예 4에서 거의 없었고, 실험예 1이 비교예 3 및 4에 비해 쓴맛이 적고, 이취가 없어 부드럽게 섭취할 수 있었고, 종합 기호도가 가장 우수하였다. As a result of the sensory test of the beverage containing the herbal medicine mixed extract according to the mixing ratio, there was almost no difference in color in Experimental Example 1, Comparative Example 3 and Comparative Example 4, and Experimental Example 1 had less bitter taste than Comparative Examples 3 and 4, and odor It was possible to eat softly because there was no
또한, 실험예 1과 염지하수가 첨가된 실험예 2는 종합적 기호도에 차이가 없었으며, 타우린, 과라나 추출물 분말 및 사양벌꿀이 혼합된 실험예 3의 음료는 실험예 1에 비해 단맛이 강화되어 더욱 편하게 섭취할 수 있어 기호도가 가장 우수하였다. In addition, Experimental Example 1 and Experimental Example 2 to which salted sewage was added had no difference in overall preference, and the beverage of Experimental Example 3, in which taurine, guarana extract powder, and fermented honey were mixed, had enhanced sweetness compared to Experimental Example 1. It was easy to ingest, so it had the best taste.
Claims (6)
2) 상기 단계 1)의 한약재 혼합물을 열수 추출하는 단계;를 포함하는 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료의 제조방법.1) after washing turmeric, jujube, arrowroot, sukjihwang, angelica, hwanggi, cheongung, goji berry, dried ginger, upper extremity, bokryeong, injin mugwort and earth worm, mixing the washed herbal material with water; and
2) hot water extraction of the herbal medicine mixture of step 1), which is effective in improving liver function, including a method for producing a herbal medicine mixture beverage with improved palatability.
1) 울금, 대추, 칡, 숙지황, 당귀, 황기, 천궁, 구기자, 건생강, 상지, 복령, 인진쑥 및 지구자를 세척한 후, 5~15%(v/v)의 염지하수가 포함된 물 100L에 대하여 상기 세척된 울금 0.8~1.2kg, 대추 0.4~0.6kg, 칡 0.4~0.6kg, 숙지황 0.08~0.12kg, 당귀 0.08~0.12kg, 황기 0.08~0.12kg, 천궁 0.08~0.12kg, 구기자 0.13~0.17kg, 건생강 0.15~0.25kg, 상지 0.8~1.2kg, 복령 0.08~0.12kg, 인진쑥 0.04~0.06kg 및 지구자 0.4~0.6kg을 혼합하는 단계; 및
2) 상기 단계 1)의 한약재 혼합물을 90~110℃에서 3~5시간 동안 열수 추출하는 단계;를 포함하는 것을 특징으로 하는 간기능 개선에 효능이 있고, 기호성이 향상된 한약재 혼합 음료의 제조방법.According to claim 1, wherein the method for preparing the beverage
1) 100L of water containing 5~15% (v/v) saltwater after washing turmeric, jujube, arrowroot, Sukjihwang, angelica, hwanggi, cheongung, gugija, dried ginger, upper extremities, bokryeong, injin mugwort and earth worm. For the above washed turmeric 0.8~1.2kg, jujube 0.4~0.6kg, kudzu 0.4~0.6kg, sukhumang 0.08~0.12kg, angelica 0.08~0.12kg, astragalus 0.08~0.12kg, cheongung 0.08~0.12kg, wolfberry 0.13~ 0.17kg, dry ginger 0.15~0.25kg, upper extremity 0.8~1.2kg, bokryeong 0.08~0.12kg, injin mugwort 0.04~0.06kg, and ginseng 0.4~0.6kg; and
2) extracting the herbal medicine mixture of step 1) with hot water at 90 ~ 110 ℃ for 3 ~ 5 hours;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190164079A KR102379824B1 (en) | 2019-12-10 | 2019-12-10 | Manufacturing method of herbal medicine mixed beverage with improved liver function and palatability and beverage produced by the same method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190164079A KR102379824B1 (en) | 2019-12-10 | 2019-12-10 | Manufacturing method of herbal medicine mixed beverage with improved liver function and palatability and beverage produced by the same method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210073341A true KR20210073341A (en) | 2021-06-18 |
KR102379824B1 KR102379824B1 (en) | 2022-03-29 |
Family
ID=76623509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190164079A KR102379824B1 (en) | 2019-12-10 | 2019-12-10 | Manufacturing method of herbal medicine mixed beverage with improved liver function and palatability and beverage produced by the same method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102379824B1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010107032A (en) * | 2000-05-24 | 2001-12-07 | 김정희 | Functional beverage and aromatic composition containing extracts from Korean medicine, products and manufacturing process thereof |
KR20090056385A (en) * | 2007-11-30 | 2009-06-03 | 한국 한의학 연구원 | Composition for alleviation of alcohol-induced hangover comprising hovenia dulcis thunberg contained ssangwhatang |
KR20100041284A (en) * | 2008-10-13 | 2010-04-22 | 홍시갑 | The method and the beverage which are good for getting out of drunken condition and for liver function |
KR20130008305A (en) * | 2011-07-12 | 2013-01-22 | 이해수 | Composition for improving liver function using an extract of wheat bran |
KR20140037699A (en) * | 2012-09-19 | 2014-03-27 | 박헌조 | A method of drink for hangover chaser containing artemisia annua l |
KR20150063186A (en) * | 2013-11-29 | 2015-06-09 | (주)휴럼 | Functional food materials and composition |
KR20160056684A (en) * | 2014-11-12 | 2016-05-20 | 조연호 | Wild plant complex fermented liquid, and manufacturing method thereof |
-
2019
- 2019-12-10 KR KR1020190164079A patent/KR102379824B1/en active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010107032A (en) * | 2000-05-24 | 2001-12-07 | 김정희 | Functional beverage and aromatic composition containing extracts from Korean medicine, products and manufacturing process thereof |
KR20090056385A (en) * | 2007-11-30 | 2009-06-03 | 한국 한의학 연구원 | Composition for alleviation of alcohol-induced hangover comprising hovenia dulcis thunberg contained ssangwhatang |
KR20100041284A (en) * | 2008-10-13 | 2010-04-22 | 홍시갑 | The method and the beverage which are good for getting out of drunken condition and for liver function |
KR20130008305A (en) * | 2011-07-12 | 2013-01-22 | 이해수 | Composition for improving liver function using an extract of wheat bran |
KR20140037699A (en) * | 2012-09-19 | 2014-03-27 | 박헌조 | A method of drink for hangover chaser containing artemisia annua l |
KR20150063186A (en) * | 2013-11-29 | 2015-06-09 | (주)휴럼 | Functional food materials and composition |
KR20160056684A (en) * | 2014-11-12 | 2016-05-20 | 조연호 | Wild plant complex fermented liquid, and manufacturing method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR102379824B1 (en) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102754751B (en) | Pig-fattening compound feed and preparation method thereof | |
KR101183605B1 (en) | The beverage composition for anti-hangover functional using cucumber vinegar | |
World Health Organization | Pellagra and its prevention and control in major emergencies | |
CN109007808A (en) | A kind of relieving alcoholism and protecting liver composition and the relieving alcoholism and protecting liver preparation comprising it | |
KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
CN107549817B (en) | Moringa oleifera natural organic calcium and preparation method thereof | |
KR20200120465A (en) | Composition for preventing or treating liver damage by alcohol which is excellent in hangover resolution | |
CN109198641A (en) | A kind of food formula and shellproof coffee prepared therefrom of low carbohydrate content | |
KR20200032772A (en) | Beverage composition for treating hangover comprising black ginseng extact | |
KR101280852B1 (en) | Fermented yam and production method thereof | |
CN106360691A (en) | Selenium-enriched food suitable for people suffering from osteoporosis and preparation method thereof | |
KR20050110413A (en) | Growth-promoting composition comprising dried yeast, extracted natural substances and nutrient mixed powder | |
KR101525478B1 (en) | Food composition for relieving hangover | |
KR102379824B1 (en) | Manufacturing method of herbal medicine mixed beverage with improved liver function and palatability and beverage produced by the same method | |
KR20120040504A (en) | Method for manufacturing fermented turmeric using a probiotic strain, lactobacills johnsonii idcc 9203 | |
KR102507651B1 (en) | Fermented Stauntonia hexaphylla for hangover relief, alcoholic liver disease or liver function improvement using fermented enzyme complex solution containing traditional brewery yeast and its manufacturing method | |
CN111357982A (en) | Sea-buckthorn compound fermentation liquor, preparation method thereof, health-care beverage and plant enzyme | |
CN109717324A (en) | A kind of feed formula and its application for layer breeding | |
KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
KR101252249B1 (en) | Fermented composition using effective micro-organisms and manufacturing method thereof | |
CN114557411A (en) | Liver-protecting and alcoholism-relieving compound beverage and preparation method thereof | |
KR20110132887A (en) | Composition for improving hepatic, stomachic function and curing hangover | |
CN101940284A (en) | Potato extract and application thereof | |
KR102383063B1 (en) | Natural fermentation vinegar using dendropanax morbiferus and dropwort, Manufacturing method thereof, and functional health food for protecting and improving a liver and kidney | |
KR102625435B1 (en) | Fermented Stauntonia hexaphylla using a natural fermented enzyme complex and a composition for bone density improvement, bone growth promotion, height growth promotion or joint health promotion using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |